Biogen Idec wins FDA approval for long-lasting hemophilia drug based on Boston Children’s technology
A few weeks ago Vector brought you the backstory of how a clotting factor for hemophilia was made to last longer in the blood, allowing injections to be pared to once every week or two, rather than two to three per week. Today we bring more good news: Following a successful Phase III trial, rFIXFc [Read More]
Promoting global child mental health
Patricia Ibeziako, MD, directs the Boston Children’s Hospital Global Partnerships for Psychiatry Observership Program and the Psychiatry Consultation Service at Boston Children’s Hospital. Children and adolescents constitute almost a third of the world’s population—2.2 billion individuals—and almost 90 percent live in low-income and middle-income countries, where they form up to half of the population. Yet, [Read More]
Who We are
The mission of the Technology and Innovation Development Office (TIDO) is to translate the excellence of the laboratory research and clinical care at Children’s Hospital Boston into lifesaving biomedical products, devices and procedures for the public benefit.
News and Events
TIDO's 2013 Annual Report Released!
TIDO reached new heights in fiscal year 2013 with respect to industry partnerships, collaborations and licenses. 34 license and option agreements were executed, an increase of 13 percent over FY12, and 29 corporate sponsored and collaboration research agreements were executed, an increase of 45 percent over FY12. The report highlights selected licenses and collaborations, Technology Development Fund award winners, and selected technologies available for licensing.
A skin cream for peripheral neuropathy? Small molecule may go a long way